Table of Contents:
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022 – 2035
2.3 Market Size & Forecast, By Segmentation, 2022 – 2035
2.3.1 Market Size By Disease Type
2.3.2 Market Size By Therapeutics Therapy
2.3.3 Market Size By Route of Administration
2.3.4 Market Size By Dosage Form
2.3.5 Market Size By Distribution Channel
2.4 Market Share & Bps Analysis By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Active Pharmaceutical Ingredient (API) Manufacturers
3.4.2 Finished Dosage Form Manufacturers and Contract Organizations
3.4.3 Government and International Procurement Agencies
3.4.4 Hospitals, Clinics, and Community Health Programs (End-Users)
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview (Infectious Disease Therapeutics)
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Treatment Outcome and Drug Efficacy Metrics
4.1.1 Overview
4.1.2 Global TB Treatment Success Rates by Drug Regimen (%)
4.1.3 Drug-Susceptible vs. Drug-Resistant TB Case Notification Trends
4.1.4 Average Treatment Duration and Completion Rate Analysis
4.1.5 Patient Adherence Metrics and Default Rate Benchmarking by Region
4.2 Drug Resistance Surveillance and Epidemiological Burden Analysis
4.2.1 Overview
4.2.2 MDR-TB and XDR-TB Incidence Rates by Region (%)
4.2.3 Molecular Diagnostics and DST (Drug Susceptibility Testing) Adoption Rates
4.2.4 Correlation Between HIV Co-Infection Rates and TB Drug Demand Volumes
4.2.5 Antimicrobial Resistance (AMR) Impact on Second-Line Therapy Market Growth
4.3 Clinical Pipeline and Drug Development Metrics
4.3.1 Overview
4.3.2 Number of Active TB Drug Candidates in Phase I, II, and III Clinical Trials
4.3.3 Regulatory Approval Timeline Analysis Across FDA, EMA, and WHO Prequalification
4.3.4 Public and Private Sector Investment in TB Drug R&D (USD Million, 2022–2024)
4.3.5 Generic Entry and Biosimilar Impact on Branded Drug Market Share Erosion
4.4 Healthcare Access, Funding, and Affordability Metrics
4.4.1 Overview
4.4.2 Global Fund and USAID TB Program Disbursement Analysis by Region
4.4.3 Domestic Financing vs. Donor Dependency by Country Income Group
4.4.4 Per-Patient Drug Cost Comparison Across First-Line and Second-Line Regimens
4.4.5 WHO Prequalification Program Impact on Generic Drug Market Penetration in LMICs
5. Tuberculosis Therapeutics Market Segmental Analysis & Forecast, By Disease Type, 2022 – 2035, Value (USD Billion)
5.1 Introduction
5.2 Active TB
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022 – 2035
5.3 Latent TB
6. Tuberculosis Therapeutics Market Segmental Analysis & Forecast, By Therapeutics Therapy, 2022 – 2035, Value (USD Billion)
6.1 Introduction
6.2 First-Line Therapy
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022 – 2035
6.3 Second-Line Therapy
7. Tuberculosis Therapeutics Market Segmental Analysis & Forecast, By Route of Administration, 2022 – 2035, Value (USD Billion)
7.1 Introduction
7.2 Oral
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022 – 2035
7.3 Parenteral
7.4 Others
8. Tuberculosis Therapeutics Market Segmental Analysis & Forecast, By Dosage Form, 2022 – 2035, Value (USD Billion)
8.1 Introduction
8.2 Tablets
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022 – 2035
8.3 Capsules
8.4 Injection
8.5 Others
9. Tuberculosis Therapeutics Market Segmental Analysis & Forecast, By Distribution Channel, 2022 – 2035, Value (USD Billion)
9.1 Introduction
9.2 Hospital Pharmacy
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2022 – 2035
9.3 Retail Pharmacy
9.4 Online Pharmacy
10. Tuberculosis Therapeutics Market Segmental Analysis & Forecast By Region, 2022 – 2035, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Tuberculosis Therapeutics Market Size & Forecast, By Disease Type, 2022 – 2035
10.2.3 Tuberculosis Therapeutics Market Size & Forecast, By Therapeutics Therapy, 2022 – 2035
10.2.4 Tuberculosis Therapeutics Market Size & Forecast, By Route of Administration, 2022 – 2035
10.2.5 Tuberculosis Therapeutics Market Size & Forecast, By Dosage Form, 2022 – 2035
10.2.6 Tuberculosis Therapeutics Market Size & Forecast, By Distribution Channel, 2022 – 2035
10.2.7 Tuberculosis Therapeutics Market Size & Forecast, By Country, 2022 – 2035
10.2.7.1 USA
10.2.7.2 Canada
10.3 Europe
10.3.1 Key Trends
10.3.2 Tuberculosis Therapeutics Market Size & Forecast, By Disease Type, 2022 – 2035
10.3.3 Tuberculosis Therapeutics Market Size & Forecast, By Therapeutics Therapy, 2022 – 2035
10.3.4 Tuberculosis Therapeutics Market Size & Forecast, By Route of Administration, 2022 – 2035
10.3.5 Tuberculosis Therapeutics Market Size & Forecast, By Dosage Form, 2022 – 2035
10.3.6 Tuberculosis Therapeutics Market Size & Forecast, By Distribution Channel, 2022 – 2035
10.3.7 Tuberculosis Therapeutics Market Size & Forecast, By Country, 2022 – 2035
10.3.7.1 Germany
10.3.7.2 UK
10.3.7.3 France
10.3.7.4 Italy
10.3.7.5 Spain
10.3.7.6 Russia
10.3.7.7 Poland
10.3.7.8 Rest of Europe
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Tuberculosis Therapeutics Market Size & Forecast, By Disease Type, 2022 – 2035
10.4.3 Tuberculosis Therapeutics Market Size & Forecast, By Therapeutics Therapy, 2022 – 2035
10.4.4 Tuberculosis Therapeutics Market Size & Forecast, By Route of Administration, 2022 – 2035
10.4.5 Tuberculosis Therapeutics Market Size & Forecast, By Dosage Form, 2022 – 2035
10.4.6 Tuberculosis Therapeutics Market Size & Forecast, By Distribution Channel, 2022 – 2035
10.4.7 Tuberculosis Therapeutics Market Size & Forecast, By Country, 2022 – 2035
10.4.7.1 China
10.4.7.2 India
10.4.7.3 Japan
10.4.7.4 South Korea
10.4.7.5 Australia
10.4.7.6 ASEAN Countries
10.4.7.7 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Key Trends
10.5.2 Tuberculosis Therapeutics Market Size & Forecast, By Disease Type, 2022 – 2035
10.5.3 Tuberculosis Therapeutics Market Size & Forecast, By Therapeutics Therapy, 2022 – 2035
10.5.4 Tuberculosis Therapeutics Market Size & Forecast, By Route of Administration, 2022 – 2035
10.5.5 Tuberculosis Therapeutics Market Size & Forecast, By Dosage Form, 2022 – 2035
10.5.6 Tuberculosis Therapeutics Market Size & Forecast, By Distribution Channel, 2022 – 2035
10.5.7 Tuberculosis Therapeutics Market Size & Forecast, By Country, 2022 – 2035
10.5.7.1 Brazil
10.5.7.2 Argentina
10.5.7.3 Mexico
10.5.7.4 Colombia
10.5.7.5 Rest of Latin America
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Tuberculosis Therapeutics Market Size & Forecast, By Disease Type, 2022 – 2035
10.6.3 Tuberculosis Therapeutics Market Size & Forecast, By Therapeutics Therapy, 2022 – 2035
10.6.4 Tuberculosis Therapeutics Market Size & Forecast, By Route of Administration, 2022 – 2035
10.6.5 Tuberculosis Therapeutics Market Size & Forecast, By Dosage Form, 2022 – 2035
10.6.6 Tuberculosis Therapeutics Market Size & Forecast, By Distribution Channel, 2022 – 2035
10.6.7 Tuberculosis Therapeutics Market Size & Forecast, By Country, 2022 – 2035
10.6.7.1 UAE
10.6.7.2 Saudi Arabia
10.6.7.3 Qatar
10.6.7.4 Egypt
10.6.7.5 South Africa
10.6.7.6 Rest of Middle East & Africa
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2025
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number Of Strategies Adopted By Key Players, 2025
11.3 Market Share Analysis, 2025
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6.1 Johnson & Johnson (Janssen Pharmaceuticals)
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Otsuka Pharmaceutical Co., Ltd.
11.6.3 Lupin Limited
11.6.4 Pfizer Inc.
11.6.5 Novartis AG
11.6.6 Sanofi S.A.
11.6.7 Viatris Inc.
11.6.8 Cipla Limited
11.6.9 Sun Pharmaceutical Industries Ltd.
11.6.10 Aurobindo Pharma Ltd.
11.6.11 Macleods Pharmaceuticals Ltd.
11.6.12 Hikma Pharmaceuticals PLC
11.6.13 Laurus Labs Ltd.
11.6.14 Mankind Pharma Ltd.
11.6.15 GlaxoSmithKline PLC
11.6.16 Daiichi Sankyo Co., Ltd.
11.6.17 Strides Pharma Science Ltd.
11.6.18 Alembic Pharmaceuticals Ltd.
11.6.19 Akums Drugs & Pharmaceuticals Ltd.
11.6.20 Astellas Pharma Inc.
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions on Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures